decitabine + cedazuridine + magrolimab

Decitabine + cedazuridine + magrolimab is a clinical-stage combination therapy under investigation for the treatment of intermediate to very high-risk myelodysplastic syndrome (MDS)[1][3][5][7]. - **Decitabine** is a DNA methyltransferase inhibitor (hypomethylating agent) that exerts antineoplastic effects by inducing DNA hypomethylation and promoting cancer cell differentiation and apoptosis[2][4][6]. - **Cedazuridine** is a cytidine deaminase inhibitor that enhances the oral bioavailability of decitabine by blocking its degradation in the gastrointestinal tract[2][4][6]. - **Magrolimab** is a monoclonal antibody that targets CD47, a macrophage immune checkpoint, serving as a "do not eat me" signal on cancer cells, and blocks it to promote phagocytosis and antitumor immune response[1][3]. This combination is being evaluated in an open-label phase 2 trial for its safety and efficacy in previously untreated adults with intermediate, high, or very high-risk MDS. The study is sponsored by Astex Pharmaceuticals and does not have an approved brand name formulation[1][3][5][7].

Brand names

Inqovi

Other names

magrolimab plus oral decitabine and cedazuridinemagrolimab + ASTX727